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The etiology of BMS remains unknown. Role of various cytokines has been implicated in the development of BMS. The aim of
this study was to evaluate levels of salivary IL-2 and IL-6 in patients with BMS, compared with age-matched healthy volunteers
(control group). Whole saliva from 30 patients with BMS, age range 55–65, was tested for the presence of IL-6 and IL-2 by enzyme
immunoassay. Control group consisted of 30 healthy participants, aged 55–65 years. Saliva IL-2 concentrations in BMS were
signiﬁcantly increased in patients compared to healthy subjects: mean 34.1 ± 9.7v e r s u s7 .3 ± 3.0pg/mL;P<. 001. Patients with
BMS had signiﬁcantly higher concentrations of IL-6 compared to control: mean 30.8 ± 5.6v e r s u s5 .2 ± 2.8pg/mL;P<. 001. In
patients with BMS, IL-2 and IL-6 levels in saliva are elevated, correlating with the severity of illness.
Copyright © 2006 Daria Simˇ ci´ c et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Burning mouth syndrome (BMS) is characterized by a con-
tinuous, painful burning sensation in a clinically normal-
appearing oral mucosa. Aﬀected patients often present mul-
tiple oral complaints, including burning, dryness, and taste
alterations.Burningmouthcomplaintsarereportedmoreof-
ten in women, especially after menopause [1]. Typically, pa-
tients awaken without pain but they note increasing symp-
toms throughout the day and into the evening. The etiology
of BMS remains unknown, although a number of local, sys-
temic and psychological factors have been proposed as being
of etiopathologic importance. Conditions that have been re-
ported in association with burning mouth syndrome include
chronic anxiety or depression, various nutritional deﬁcien-
cies, type 2 diabetes, and changes in salivary function [2].
However, these conditions have not been consistently linked
to the syndrome, and their treatment has had little impact
on burning mouth symptoms. Recent studies have pointed
to dysfunction of several cranial nerves associated with taste
sensation as a possible cause of burning mouth syndrome
[3]. In more than one half of the patients with burning
mouth syndrome, the onset of pain is spontaneous, with no
identiﬁable precipitating factor. Approximately, one third of
the patients relate onset time to a dental procedure, recent
illness, or medication course (including antibiotic therapy).
Regardless of the nature of pain onset, once the oral burn-
ing starts, it often persists for many years [4]. The burning
sensation often occurs in more than one oral site, with the
anterior two thirds of the tongue, the anterior hard palate
and the lower lip mucosa being the most frequently involved
[5].
As a nonspeciﬁc antigen proliferative factor for all T-
lymphocyte subpopulations, IL-2 is an immune regulator
playing a major role in inﬂammatory reactions as well as in
tumor control. During inﬂammation, IL-2 stimulates secre-
tion of proinﬂammatory cytokines such as IL-1, TNF-α,a n d
TNF-β [6].
IL-6 is a pleotropic cytokine that inﬂuences the antigen-
speciﬁc immune responses and inﬂammatory reactions. To-
gether with IL-1 and TNF-α (which also stimulate IL-6 se-
cretion), it belongs to the group of main proinﬂammatory
cytokines [7].
The causes of BMS and the pathogenic mechanisms be-
hind it are still unknown. The etiology is presumed to be
multifactorial, involving an interaction between biological
and psychological factors. A considerable number of local,
oral factors have been found to relate to BMS, including xe-
rostomia, hyposalivation, taste disturbance, oral candidiasis,
temporomandibular functional disorders, and allergic reac-
tions [8].2 Mediators of Inﬂammation
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Figure 1: Comparison of IL-2 and IL-6 levels in the patients with
BMS and healthy individuals (controls). Data represent the mean
logcytokinecontent(IQR)inpgpermilliliterofsalivaderivedfrom
30 subjects.
SUBJECTS AND METHODS
Thirty patients with BMS were included in this study. Thirty
age-matched healthy volunteers served as a control group.
Clinical examination was performed according to the stan-
dard clinical criteria. After informed consent had been ob-
tained and medical, dental, and social histories collected,
each individual expectorated 10mL of unstimulated whole
saliva into a sterile centrifuge tube. Saliva specimens were
collected from each participant in sitting position. After-
wards, the saliva specimens were stored at −80◦C until the
beginning of analysis. For determination of salivary levels of
IL-2 and IL-6, ELISA (Sigma Immunochemicals, St Louis,
Mo, USA) was performed. The assay was performed accord-
ing to the manufacturer’s instructions, and the results are ex-
pressed in pg/mL. The detection limit for both IL-2 and IL-6
was 4.6pg/mL.
STATISTICAL ANALYSIS
Data are presented as means with standard deviations, and
as median values with interquartile range (IQR) and a loga-
rithmic scale. The results obtained were compared using the
nonparametric Wilcoxon test and one-way ANOVA test. Sta-
tistically signiﬁcant diﬀerence was deﬁned at P<. 05.
RESULTS
The levels of IL-2 and IL-6 were measured in the whole saliva
of control group, as well as in the patients with BMS, and
are presented as the median (IQR) on a logarithmic scale in
Figure 1.
Concentration of IL-2 was measured in saliva samples of
30 patients suﬀering from burning mouth syndrome, as well
as 30 healthy subjects. Average value of IL-2 concentration
was signiﬁcantly higher in the group of patients with BMS:
mean 34.1 ± 9.7pg/mL compared to control group: mean
7.3 ± 3.0pg/mL(P<. 001). Statistical diﬀerence was signif-
icant at the level of P<. 001. Median value for IL-2 level
in the group with BMS: 34.9( I Q R :3 2 .5–40.0)pg/mL was
signiﬁcantly higher (P<. 001), compared to 7.3( I Q R :5 .6–
11.4)pg/mL in healthy subjects.
Concentration of IL-6 was determined in saliva speci-
mens of 30 patients suﬀering from BMS and 30 healthy in-
dividuals from control group.
Average value of IL-6 concentration was signiﬁcantly
higher in experimental group: mean 30.8 ± 5.6pg/mL com-
pared to values obtained in control group: mean 5.2 ±
2.8pg/mL.Thediﬀerence was statistically signiﬁcant at the
level of P<. 001. Median value of IL-6 level in the group
of patients with BMS: 30.5( I Q R :2 8 .4–33.2)pg/mL was sig-
niﬁcantly higher (P<. 001) compared to 4.4( I Q R :2 .4–
7.0)pg/mL in control group. It can be noted that the high-
est value of IL-6 in control group was lower than the lowest
value of IL-6 in the patients with BMS.
DISCUSSION
Burning mouth syndrome is characterized by a burning sen-
sation of the tongue or other oral sites, usually in the absence
of clinical and laboratory ﬁndings. Aﬀected patients often
present multiple oral complaints, including burning, dry-
ness, and taste alterations. Pain is one of the common sen-
sations which usually indicate tissue damage as a conse-
quence of various external or internal factors [9]. Neverthe-
less,persistingpainthatdoesnotmeetcriteriaforsomeother
cranial neuralgia or other generally described painful syn-
drome is described by Headache Society as atypical orofacial
pain. Such pain does not follow the usual anatomical pain
routes or related physiological mechanisms, cannot be alle-
viated by cutting oﬀ the nerve path, and lacks the identifying
neuropathic, extraneural, or central origin [10]. Atypical fa-
cial pain, together with stomatodynia (where some authors
group BMS), atypical odontalgia, and masticatory muscle
and temporomandibular joint (TMJ) disorders, as well as id-
iopathic dysgeusia form the category of idiopathic orofacial
pain [11]. Despite the existence of numerous studies dealing
with the problem of atypical painful disorders etiology, clear
causative factor or mechanism of this painful condition has
not yet been deﬁned. Possible local, systemic, neurological,
and psychological factors are repeatedly analyzed [12, 13].
Since there are numerous eﬀects of IL-6 in organisms,
andsubsequentlyinorofacialarea,itspresenceandincreased
concentration in saliva of the patients with BMS conﬁrms
the hypothesis of the role of IL-6 in BMS genesis. Depres-
sion is a common occurrence in the patients with atypical
painful conditions and BMS. Controversy in available litera-
ture is whether depression leads to BMS or it is a secondary
consequence of chronic painful condition [14]. Statistically
signiﬁcant ﬁnding of cytokines in our research, as well asDaria Simˇ ci´ ce ta l 3
presence of cytokines IL-2 and IL-6 which are analyzed in
relation to depression, conﬁrms the existence of relationship
between depression and BMS.
Our ﬁndings can be correlated to the research conducted
by Xia et al [15] who studied levels of IL-2 and IL-6 in sera of
thepatients withor withoutdepression, suﬀeringfromBMS.
They reported that there was no statistically signiﬁcant dif-
ference in serum levels of IL-2 and IL-6 in the patients with
BMS who also suﬀered from depression, compared to indi-
viduals with BMS and without depression. Their conclusion
was that depression does not necessarily inﬂuence the serum
levels of IL-2 and IL-6, but it is possibly related to BMS. Pres-
ence of IL-2 and IL-6 in their patients with BMS corresponds
toourﬁndings.Thediﬀerencebetweenthetwoisthatabove-
mentioned authors proved the presence of increased serum
levels of IL-2 and IL-6, while in our research increased con-
centrations of IL-2 and IL-6 were also detected in saliva.
S t r e c k f u se ta l[ 16] detected increased concentrations of
IL-2 and IL-6 in saliva specimens of the patients suﬀering
from Sj¨ ogren syndrome. Destructive changes in the glands
can therefore be related to immunological and inﬂamma-
tory responses. Forty six to seventy six percent of the patients
with BMS complain of dry mouth [17]. Such connection
between BMS and dry mouth could aﬀect accumulation of
thepain symptoms; burning sensations; feeding, swallowing,
and speech diﬃculties; as well as negative inﬂuence on qual-
ity of life. In some patients with BMS who complain of dry
mouth, changes in both quality and quantity of saliva can be
easily detected [18]. Although the relationship between dry
mouth and BMS has already been proved, role of decreased
salivaryﬂow,orfeelingofdrymouthinthepatientssuﬀering
from BMS has not been entirely elucidated, or recognized for
that matter. This research proved existence of IL-2 and IL-6
in all saliva specimens. In patients with BMS, concentration
of these cytokines was increased and statistically signiﬁcant.
This supports the assumption that IL-2 and IL-6 are objec-
tive markers for diagnostics and detection of painful condi-
tion BMS.
Available literature fails to oﬀer us a single position re-
garding the cause of BMS development. Authors commonly
conclude that in order to assess BMS development, one must
take into consideration a variety of causative factors, which
are not common for the majority of patients. A certain BMS
causative factor in one patient does not necessarily cause
burning sensations—pain in another individual suﬀering
from the same problem. Diﬀerent, multiple activities of IL-
2 conﬁrm such hypothesis for BMS development. Increased
IL-2 concentration in this research oﬀers a possible explana-
tion for the causative mechanism of BMS through immuno-
logical reactions during inﬂammation.
Due to the fact that BMS is a multicausal disorder, the
most rational approach would be to analyze multiple im-
munologically active substances, since their production and
eﬀect depend upon numerous, diverse, and overlapping fac-
tors. Future research should be based on combined analyses
of immunologically active substances, which might be use-
ful for BMS risk assessment and quality of designated ther-
apy.
Oralﬂuidbeingthe“mirrorofbody”isaperfectmedium
to be explored for health and disease monitoring. The trans-
lational applications and opportunities are enormous. The
ability to monitor health status, disease onset and progres-
sion, and treatment outcome monitoring through noninva-
sive means is the most desirable goal in the health care pro-
motion and delivery.
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